profit from every $100 of sales.
$0$100
Gelteq Limited Ordinary Shares
$0.38-0.13% today
-87.4% in 1 year
1-year low $0.381-year high $3.72
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Gelteq Limited Ordinary Shares sold, what it kept, and what it did with the cash.
Sales went from A$147,536 in 2022 to A$165,645 in 2025, with -A$6.65 million of profit last year.
SalesProfit
Gelteq Limited Ordinary Shares vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Gelteq Limited Ordinary Shares | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Gelteq Limited Ordinary Shares's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | – | |
| -3 | -3 | -3 | -5 | |
| -2 | -2 | -2 | -4 | |
| -3 | -4 | -4 | -7 | |
| -0.36 | -0.37 | -0.38 | – | |
| 35.7% | 38.7% | – | – | |
| -2,165.1% | -4,232.9% | – | -2,989.0% | |
| -2,283.4% | -4,391.4% | – | -4,011.9% |
Balance sheet
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 23 | 22 | 21 | 21 |
| Cash | 0 | 0 | 0 | 0 |
| Total debt | 2 | 2 | 4 | 4 |
| Total liabilities | 3 | 4 | 6 | 6 |
| 21 | 19 | 15 | 16 | |
| 9 | 9 | 9 | – | |
| -11.3% | -11.6% | -12.3% | -18.7% | |
| -16.2% | -18.8% | -23.5% | -42.0% |
Cash flow
| In millions of AUD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | – | – | – | |
| – | 0 | 0 | 1 | |
| -2 | -2 | -1 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- –
- –
- –
- 0.0×
- 36.3×
- –
- –
- -102.5%
- -110.5%
- 0.0%
Profitability
- 100.0%
- -2,989.0%
- -4,011.9%
- -2,129.8%
- -27.4%
- -17.2%
- -43.0%
- -30.9%
- -34.7%
- 379.5%
Growth
- +3.9%
- –
- −405.8%
- –
- –
Financial health
- –
- 0.27
- 19.6%
- -2.9×
- 0.27
- 0.27
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 952
Bottom 27%of 888
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
57No pass
Philip Fisher
53No pass
Peter Lynch
48No pass
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
43No pass
Questions about Gelteq Limited Ordinary Shares
Is Gelteq Limited Ordinary Shares a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Gelteq Limited Ordinary Shares AI analysis
What does Gelteq Limited Ordinary Shares do?
Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. It is in Drug Manufacturers - Specialty & Generic.
Does Gelteq Limited Ordinary Shares pay a dividend?
No. Gelteq Limited Ordinary Shares does not pay a dividend at the moment.
Is Gelteq Limited Ordinary Shares stock halal?
No. Gelteq Limited Ordinary Shares does not pass our halal screen: its debt is 70% of its market value, at or above the 33% limit. How we check
How has Gelteq Limited Ordinary Shares stock done over the past year?
Down 87.4% over the past twelve months, to $0.38. It traded between $0.38 and $3.72 and is 89.8% below its high.
Who are Gelteq Limited Ordinary Shares's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Gelteq Limited Ordinary Shares's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.